Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jun 20th (reported today). The aggregated short interest was USD25.9bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia, Evolution Mining, BHP, National Australia Bank, Westpac.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jun 20th (reported today). The aggregated short interest was USD25.9bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia, Evolution Mining, BHP, National Australia Bank, Westpac.


ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/clarity-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:34095:1" rel="noopener">Clarity Pharmaceuticals Ltd (CU6 AU)</a> initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.</li>
<li>The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.</li>
<li>Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. </li>
</ul>



Clarity Pharmaceuticals Ltd (CU6 AU) initiated Phase 3 trial for its lead diagnostic candidate 64Cu-SARbisPSMA. The trial intends to gather data for filing of the product.
The company’s cash position at the end of the March quarter was A$95M, with additional A$11M received in April for FY24 R&amp;D tax incentive. This provides cash runway through 2H26.
Clarity has built a robust supply of copper-64 with a wide network of product manufacturers in preparation for its two Phase 3 trials in prostate cancer and potential commercialization. 


Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of Jun 13th (reported today). The aggregated short interest was USD27.1bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Northern Star Resources, Cochlear, Commonwealth Bank Of Australia, Sigma Pharmaceuticals, Evolution Mining, Brambles.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of Jun 13th (reported today). The aggregated short interest was USD27.1bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Northern Star Resources, Cochlear, Commonwealth Bank Of Australia, Sigma Pharmaceuticals, Evolution Mining, Brambles.


ASX Short Interest Weekly (Jun 13th): Northern Star Resources, Cochlear

<ul>
<li>
<a href="https://www.smartkarma.com/entities/telix-pharmaceuticals-ltd" target="_blank" data-smartkarma-citation="entities:26052:1" rel="noopener">Telix Pharmaceuticals (TLX AU)</a> has launched next-generation prostate cancer imaging agent, Gozellix in the U.S. With two FDA-approved commercial products, current U.S. addressable market opportunity is $2.5B+.</li>
<li>The FDA is expected to communicate its decision regarding the approval of Zircaix, kidney cancer imaging candidate, on August 27. Telix estimates initial U.S. market opportunity for Zircaix is $500M+.</li>
<li>Illuccix continued its momentum through gaining market share and maintaining price stability in a competitive landscape. In 1Q25, Illuccix revenue increased 35% YoY and 9% QoQ to $151M.</li>
</ul>



Telix Pharmaceuticals (TLX AU) has launched next-generation prostate cancer imaging agent, Gozellix in the U.S. With two FDA-approved commercial products, current U.S. addressable market opportunity is $2.5B+.
The FDA is expected to communicate its decision regarding the approval of Zircaix, kidney cancer imaging candidate, on August 27. Telix estimates initial U.S. market opportunity for Zircaix is $500M+.
Illuccix continued its momentum through gaining market share and maintaining price stability in a competitive landscape. In 1Q25, Illuccix revenue increased 35% YoY and 9% QoQ to $151M.


Telix Pharmaceuticals (TLX AU): New Product Launch In US; More to Follow; Illuccix on Strong Footing

<ul>
<li>We analyzed the changes in short interest of ASX Stocks as of May 23rd (reported today). The aggregated short interest was USD26.7bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in National Australia Bank, Goodman, ANZ, Asx.</li>
</ul>


We analyzed the changes in short interest of ASX Stocks as of May 23rd (reported today). The aggregated short interest was USD26.7bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in National Australia Bank, Goodman, ANZ, Asx.


ASX Short Interest Weekly (May 23rd): National Australia Bank, Goodman, ANZ, Asx

Australia

Opthea Limited is a biologics drug developer for ophthalmic diseases. The Company develops therapies for diabetic macular edema, corneal neovascularization and transplantation, and dry eye disease. Opthea serves patients and healthcare providers in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Opthea Ltd (OPT AU)

ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

We analyzed ASX short interest report for the past week and highlight short interest changes in Sigma Pharmaceuticals (SIG AU), Brambles (BXB AU),...

Ke Yan, CFA, FRM

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

ASX Short Interest Weekly (Jun 13th): Northern Star Resources, Cochlear

We analyzed ASX short interest report for the past week and highlight short interest changes in Northern Star Resources (NST AU), Cochlear (COH...

Ke Yan, CFA, FRM

Telix Pharmaceuticals (TLX AU): New Product Launch In US; More to Follow; Illuccix on Strong Footing

Telix Pharmaceuticals launches new prostate cancer imaging agent in the U.S., with FDA decision on kidney cancer imaging candidate expected soon....

Tina Banerjee

ASX Short Interest Weekly (May 23rd): National Australia Bank, Goodman, ANZ, Asx

We analyzed ASX short interest report for the past week and highlight short interest changes in National Australia Bank, Goodman, ANZ, Asx.

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ASX Short Interest Weekly (Jun 20th): Sigma Pharmaceuticals, Brambles, Cochlear, Yancoal Australia

We analyzed ASX short interest report for the past week and highlight short interest changes in Sigma Pharmaceuticals (SIG AU), Brambles (BXB AU),...

Ke Yan, CFA, FRM

Clarity Pharmaceuticals Ltd (CU6 AU): Steady Progress Toward Commercialization

​Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Tina Banerjee

ASX Short Interest Weekly (Jun 13th): Northern Star Resources, Cochlear

We analyzed ASX short interest report for the past week and highlight short interest changes in Northern Star Resources (NST AU), Cochlear (COH...

Ke Yan, CFA, FRM

Telix Pharmaceuticals (TLX AU): New Product Launch In US; More to Follow; Illuccix on Strong Footing

​Telix Pharmaceuticals launches new prostate cancer imaging agent in the U.S., with FDA decision on kidney cancer imaging candidate expected soon....

Tina Banerjee

ASX Short Interest Weekly (May 23rd): National Australia Bank, Goodman, ANZ, Asx

We analyzed ASX short interest report for the past week and highlight short interest changes in National Australia Bank, Goodman, ANZ, Asx.

Ke Yan, CFA, FRM

Clarity Pharmaceuticals initiates Phase 3 trial for lead diagnostic candidate, with strong cash position and supply chain in place for future...

Telix Pharmaceuticals launches new prostate cancer imaging agent in the U.S., with FDA decision on kidney cancer imaging candidate expected soon....